¼¼°èÀÇ È¿¼Ò¸é¿ªÃøÁ¤¹ý ½ÃÀå
Enzyme Immunoassays
»óǰÄÚµå : 1773816
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 487 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,112,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,338,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

È¿¼Ò¸é¿ªÃøÁ¤¹ý ¼¼°è ½ÃÀåÀº 2030³â±îÁö 211¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 178¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â È¿¼Ò¸é¿ªÃøÁ¤¹ý ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 2.9%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 211¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ½Ã¾à¡¤Å°Æ®´Â CAGR 2.7%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 132¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ºÐ¼®±â/±â±â ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 3.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 49¾ï ´Þ·¯, Áß±¹Àº CAGR 5.4%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ È¿¼Ò¸é¿ªÃøÁ¤¹ý ½ÃÀåÀº 2024³â¿¡ 49¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 41¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 5.4%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 1.1%¿Í 2.2%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 1.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ È¿¼Ò¸é¿ªÃøÁ¤¹ý ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

È¿¼Ò¸é¿ªÃøÁ¤¹ý(EIA)ÀÌ Áø´Ü °Ë»ç¿¡¼­ Á¡Á¡ ´õ Áß¿äÇØÁö´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

È¿¼Ò¸é¿ªÃøÁ¤¹ý(EIA)Àº ¹ÙÀÌ¿À¸¶Ä¿, º´¿øÃ¼, Ç×ü¸¦ ½Å¼Ó, °í°¨µµ, ƯÀÌÀûÀ¸·Î °ËÃâÇÏ´Â Áø´Ü °Ë»ç¿¡¼­ Áß¿äÇÑ µµ±¸°¡ µÇ¾ú½À´Ï´Ù. ÀÌ ±â¼úÀº ³ôÀº 󸮷®°ú Àú³óµµÀÇ Ç¥Àû ºÐÀÚ¸¦ °ËÃâÇÒ ¼ö ÀÖ´Â ´É·ÂÀ¸·Î ÀÇ·á Áø´Ü, Á¦¾à ¿¬±¸, ȯ°æ °Ë»ç¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. °¨¿°¼º Áúȯ, ÀÚ°¡¸é¿ªÁúȯ, ¾Ï ¹× ½ÉÇ÷°üÁúȯ°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡°¡ EIA ±â¹Ý Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

È¿¼Ò °áÇÕ ¸é¿ª ÈíÂø¹ý(ELISA), È­Çй߱¤¸é¿ªÃøÁ¤¹ý(CLIA), ´ÙÁß ¸é¿ª ÃøÁ¤¹ý °³¹ß µî ÃøÁ¤¹ý ¼³°èÀÇ ±â¼úÀû ¹ßÀüÀ¸·Î ¹Î°¨µµ¿Í ƯÀ̵µ°¡ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ÀÚµ¿È­¿Í ÇöÀå °Ë»ç(POC)·ÎÀÇ ÀüȯÀº ÀÓ»ó ½ÇÇè½Ç ¹× °¡Á¤ Áø´Ü¿¡¼­ EIAÀÇ Ã¤ÅÃÀ» ´õ¿í È®´ë½Ã۰í ÀÖ½À´Ï´Ù. Áúº´ÀÇ Á¶±â ¹ß°ß°ú ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä´Â ½Å¼ÓÇϰí Á¤È®ÇÑ Áø´Ü °á°ú¸¦ Á¦°øÇÏ´Â »õ·Î¿î ¸é¿ªÃøÁ¤¹ý ¿¬±¸¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

±â¼ú Çõ½ÅÀº È¿¼Ò ¸é¿ª ÃøÁ¤¹ýÀÇ È¿À²¼ºÀ» ¾î¶»°Ô Çâ»ó½Ã۰í Àִ°¡?

ÃÖ±Ù È¿¼Ò¸é¿ªÃøÁ¤¹ýÀÇ ±â¼ú Çõ½ÅÀº ºÐ¼® ¼º´ÉÀ» Çâ»ó½Ã۰í, ³³±â¸¦ ´ÜÃàÇϸç, ÀÚµ¿È­ ´É·ÂÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¹Ì¼¼À¯Ã¼ ±â¼úÀÇ ÅëÇÕÀ¸·Î ¼ÒÇüÈ­µÈ °í󸮷® ¸é¿ªÃøÁ¤¹ý Ç÷§ÆûÀÇ °³¹ßÀÌ °¡´ÉÇØÁ® ½Ã¾à ¼Òºñ¸¦ ÁÙÀ̸鼭 È¿À²À» ³ôÀÏ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ³ª³ë±â¼úÀÇ ¹ßÀüÀº Áúº´ ¹ÙÀÌ¿À¸¶Ä¿¸¦ Á¶±â¿¡ °ËÃâÇÒ ¼ö ÀÖ´Â Ãʹΰ¨¼º ¸é¿ªÃøÁ¤¹ý¹ý °³¹ß¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×Àº ¸é¿ªÃøÁ¤ °á°ú¸¦ º¸´Ù Á¤È®ÇÏ°Ô ºÐ¼®Çϰí, ÀÎÀ§Àû ¿À·ù¸¦ ÁÙÀ̰í, Áø´Ü Á¤È®µµ¸¦ Çâ»ó½Ã۱â À§ÇØ È°¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀçÁ¶ÇÕ È¿¼Ò ¹× Àΰø Ç×üÀÇ »ç¿ëÀº ±³Â÷ ¹ÝÀÀ¼ºÀ» ÁÙÀÌ°í ºÐ¼®ÀÇ Æ¯À̼ºÀ» ³ô¿© EIAÀÇ ½Å·Ú¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ½Å¼ÓÇÏ°í ºñ¿ë È¿À²ÀûÀÌ¸ç ½Å·ÚÇÒ ¼ö ÀÖ´Â Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó È¿¼Ò¸é¿ªÃøÁ¤¹ý ½ÃÀåÀº ƯÈ÷ °¨¿°¼º Áúȯ °Ë»ç ¹× ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ °ËÃ⠺о߿¡¼­ Áö¼ÓÀûÀÎ ¹ßÀüÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

È¿¼Ò¸é¿ªÃøÁ¤¹ý ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?

È¿¼Ò¸é¿ªÃøÁ¤¹ý ½ÃÀåÀÇ ¼ºÀåÀº °¨¿°¼º Áúȯ ¹ßº´·ü Áõ°¡, ÇöÀå Áø´Ü ¼Ö·ç¼ÇÀÇ Ã¤Åà Áõ°¡, ¸é¿ªÃøÁ¤ ±â¼úÀÇ ¹ßÀü µî ¿©·¯ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. Áúº´ÀÇ Á¶±â ¹ß°ß¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö ¿¬±¸ÀÇ È®´ë´Â °í°¨µµ, °íƯÀ̵µÀÇ EIA ±â¹Ý °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Áø´ÜÀÇ Áøº¸¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú Á¤ºÎÀÇ ÀçÁ¤Àû Áö¿øÀÌ ½ÃÀå È®´ë¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

ƯÈ÷ ¸¸¼ºÁúȯ ÀÚ°¡ ¸ð´ÏÅ͸µ ¹× °¨¿°¼º Áúȯ °Ë»ç¸¦ À§ÇÑ °¡Á¤¿ë ¹× ÈÞ´ë¿ë ¸é¿ªÃøÁ¤ ŰƮÀÇ µîÀåÀº ½ÃÀå ¼ºÀå¿¡ ´õ¿í ±â¿©Çϰí ÀÖ½À´Ï´Ù. Á¦¾à ¹× »ý¸í°øÇÐ »ê¾÷µµ ÀǾàǰ °³¹ß, Ä¡·á ¸ð´ÏÅ͸µ, ¹é½Å ¿¬±¸ ºÐ¾ß¿¡¼­ ¸é¿ªÃøÁ¤¹ý¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¿Í ¿¬±¸ÀÚµéÀÌ Á¤¹Ð Áø´Ü¿¡ ´ëÇÑ ÅõÀÚ¸¦ Áö¼ÓÇÏ´Â °¡¿îµ¥, Áø´Ü °Ë»çÀÇ ¼Óµµ, Á¤È®¼º, ÀÚµ¿È­ Çâ»ó¿¡ ÃÊÁ¡À» ¸ÂÃá ±â¼ú Çõ½ÅÀ¸·Î È¿¼Ò¸é¿ªÃøÁ¤¹ý ½ÃÀåÀº Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÎ¹®

Á¦Ç°(½Ã¾à ¹× ŰƮ, ºÐ¼®±â/±â±â, ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º), °Ëü(Ç÷¾×, Ÿ¾×, ¼Òº¯, ±âŸ °Ëü), ¿ëµµ(Ä¡·áÁ¦ ¸ð´ÏÅ͸µ, Á¾¾çÇÐ, ¼øÈ¯±âÇÐ, ³»ºÐºñÇÐ, °¨¿°Áõ °Ë»ç, ÀÚ°¡¸é¿ªÁúȯ, ±âŸ), ÃÖÁ¾ ¿ëµµ(º´¿ø, Ç÷¾×ÀºÇà, ÀÓ»ó °Ë»ç½Ç, Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷, Çмú ¿¬±¸ ¼¾ÅÍ, ±âŸ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Enzyme Immunoassays Market to Reach US$21.1 Billion by 2030

The global market for Enzyme Immunoassays estimated at US$17.8 Billion in the year 2024, is expected to reach US$21.1 Billion by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Reagents & Kits, one of the segments analyzed in the report, is expected to record a 2.7% CAGR and reach US$13.2 Billion by the end of the analysis period. Growth in the Analyzers / Instruments segment is estimated at 3.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.9 Billion While China is Forecast to Grow at 5.4% CAGR

The Enzyme Immunoassays market in the U.S. is estimated at US$4.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.1 Billion by the year 2030 trailing a CAGR of 5.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Enzyme Immunoassay Market - Key Trends & Drivers Summarized

Why Is Enzyme Immunoassay (EIA) Gaining Importance in Diagnostic Testing?

Enzyme immunoassay (EIA) has become a critical tool in diagnostic testing, providing rapid, sensitive, and specific detection of biomarkers, pathogens, and antibodies. The technique is widely used in medical diagnostics, pharmaceutical research, and environmental testing due to its high-throughput capabilities and ability to detect even low concentrations of target molecules. The increasing prevalence of infectious diseases, autoimmune disorders, and chronic conditions such as cancer and cardiovascular diseases is driving the demand for EIA-based diagnostic solutions.

Technological advancements in assay design, such as the development of enzyme-linked immunosorbent assay (ELISA) variants, chemiluminescent immunoassays (CLIA), and multiplex immunoassays, have improved sensitivity and specificity. The shift toward automation and point-of-care (POC) testing is further expanding the adoption of EIA in clinical laboratories and home-based diagnostics. The demand for early disease detection and personalized medicine is fueling research into novel immunoassay formats that provide rapid and highly accurate diagnostic results.

How Are Innovations Enhancing the Efficiency of Enzyme Immunoassays?

Recent innovations in enzyme immunoassays are improving assay performance, reducing turnaround times, and increasing automation capabilities. The integration of microfluidic technology is enabling the development of miniaturized and high-throughput immunoassay platforms, which enhance efficiency while reducing reagent consumption. Additionally, advancements in nanotechnology are contributing to the development of ultra-sensitive immunoassays that can detect disease biomarkers at an early stage.

Artificial intelligence (AI) and machine learning are being leveraged to analyze immunoassay results more accurately, reducing human errors and improving diagnostic precision. The use of recombinant enzymes and engineered antibodies is enhancing the reliability of EIA by reducing cross-reactivity and increasing assay specificity. As demand for rapid, cost-effective, and reliable diagnostic tools grows, the enzyme immunoassay market is expected to witness continuous advancements, particularly in infectious disease testing and cancer biomarker detection.

What Are the Key Factors Driving Growth in the Enzyme Immunoassay Market?

The growth in the enzyme immunoassay market is driven by several factors, including the rising incidence of infectious diseases, increasing adoption of point-of-care diagnostic solutions, and advancements in immunoassay technology. The growing need for early disease detection and the expansion of research in biomarker discovery are fueling the demand for highly sensitive and specific EIA-based tests. Additionally, regulatory approvals and government funding for diagnostic advancements are supporting market expansion.

The rise of home-based and portable immunoassay kits, particularly for self-monitoring of chronic diseases and infectious disease testing, is further contributing to market growth. The pharmaceutical and biotechnology industries are also driving demand for immunoassays in drug development, therapeutic monitoring, and vaccine research. As healthcare providers and researchers continue to invest in precision diagnostics, the enzyme immunoassay market is expected to expand significantly, with innovations focused on improving speed, accuracy, and automation in diagnostic testing.

SCOPE OF STUDY:

The report analyzes the Enzyme Immunoassays market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Reagents & Kits, Analyzers / Instruments, Software & Services); Specimen (Blood, Saliva, Urine, Other Specimens); Application (Therapeutic Drug Monitoring, Oncology, Cardiology, Endocrinology, Infectious Disease Testing, Autoimmune Diseases, Others); End-Use (Hospitals, Blood Banks, Clinical Laboratories, Pharma & Biotech Companies, Academic Research Centers, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â